Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension

Guang Yang, Zihu Tan, Ling Zhou, Min Yang, Lang Peng, Jinjin Liu, Jingling Cai, Ru Yang, Junyan Han, Yafei Huang, Shaobin He
doi: https://doi.org/10.1101/2020.03.31.20038935
Guang Yang
1Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430070, China
2Hubei Provincial Academy of Traditional Chinese Medicine, Wuhan, 430070, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zihu Tan
1Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430070, China
2Hubei Provincial Academy of Traditional Chinese Medicine, Wuhan, 430070, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ling Zhou
4Zhongnan Hospital of Wuhan University, Wuhan, 430071, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min Yang
5Department of Preventive Medicine, School of Basic Medicine, Hubei University of Chinese Medicine, Wuhan, 430070, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lang Peng
1Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430070, China
2Hubei Provincial Academy of Traditional Chinese Medicine, Wuhan, 430070, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinjin Liu
1Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430070, China
2Hubei Provincial Academy of Traditional Chinese Medicine, Wuhan, 430070, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingling Cai
1Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430070, China
2Hubei Provincial Academy of Traditional Chinese Medicine, Wuhan, 430070, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ru Yang
6Wuhan Blood Center, Wuhan, 430030, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junyan Han
7Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yafei Huang
3Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Geriatrics_HBSZYY@163.com huangy2018@hust.edu.cn
Shaobin He
1Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430070, China
2Hubei Provincial Academy of Traditional Chinese Medicine, Wuhan, 430070, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Geriatrics_HBSZYY@163.com huangy2018@hust.edu.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

With the capability of inducing elevated expression of ACE2, the cellular receptor for SARS-CoV-2, angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ARBs/ACEIs) treatment may have a controversial role in both facilitating virus infection and reducing pathogenic inflammation. We aimed to evaluate the correlation of ARBs/ACEIs usage with the pathogenesis of COVID-19 in a retrospective, single-center study. 126 COVID-19 patients with preexisting hypertension at Hubei Provincial Hospital of Traditional Chinese Medicine (HPHTCM) in Wuhan from January 5 to February 22, 2020 were retrospectively allocated to ARBs/ACEIs group (n=43) and non-ARBs/ACEIs group (n=83) according to their antihypertensive medication. 125 age- and sex-matched COVID-19 patients without hypertension were randomly selected as non-hypertension controls. In addition, the medication history of 1942 hypertension patients that were admitted to HPHTCM from November 1 to December 31, 2019 before COVID-19 outbreak were also reviewed for external comparison. Epidemiological, demographic, clinical and laboratory data were collected, analyzed and compared between these groups. The frequency of ARBs/ACEIs usage in hypertension patients with or without COVID-19 were comparable. Among COVID-19 patients with hypertension, those received either ARBs/ACEIs or non-ARBs/ACEIs had comparable blood pressure. However, ARBs/ACEIs group had significantly lower concentrations of CRP (p=0.049) and procalcitonin (PCT, p=0.008). Furthermore, much lower proportion of critical patients (9.3% vs 22.9%; p=0.061), and a lower death rate (4.7% vs 13.3%; p=0.216) were observed in ARBs/ACEIs group than non-ARBs/ACEIs group, although these differences failed to reach statistical significance. Our findings thus support the use of ARBs/ACEIs in COVID-19 patients with preexisting hypertension.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by research grants from the National Natural Science Foundation of China (2017NSFC81670825 and 2020NSFC31970865).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

After publication, the data will be made available to others on reasonable requests to the corresponding author. A proposal with detailed description of study objectives and statistical analysis plan will be needed for evaluation of the reasonability of requests. Additional materials might also be required during the process of evaluation. Deidentified participant data will be provided after approval from the corresponding author and Hubei Provincial Hospital of Traditional Chinese Medicine.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 04, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension
Guang Yang, Zihu Tan, Ling Zhou, Min Yang, Lang Peng, Jinjin Liu, Jingling Cai, Ru Yang, Junyan Han, Yafei Huang, Shaobin He
medRxiv 2020.03.31.20038935; doi: https://doi.org/10.1101/2020.03.31.20038935
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension
Guang Yang, Zihu Tan, Ling Zhou, Min Yang, Lang Peng, Jinjin Liu, Jingling Cai, Ru Yang, Junyan Han, Yafei Huang, Shaobin He
medRxiv 2020.03.31.20038935; doi: https://doi.org/10.1101/2020.03.31.20038935

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8786)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1863)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (492)
  • Hematology (207)
  • HIV/AIDS (394)
  • Infectious Diseases (except HIV/AIDS) (10563)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1755)
  • Nursing (103)
  • Nutrition (266)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (965)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (265)
  • Primary Care Research (219)
  • Psychiatry and Clinical Psychology (1844)
  • Public and Global Health (3985)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (535)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)